I have been using DHEA supplements for at least 6 years, and I really like the extra energy, sexual interest, and zest for
life that it has given me. But I’ve read that the U.S. government is planning to criminalize the possession of DHEA as part
of its War On Drugs. Government officials claim that DHEA has no medical value and is dangerous. To me, the part about no
medical value seems like an outright lie — it has certainly been of value to me, and also, I think, to many others. Can you
tell me what is known about this subject? I see no reason why I should be considered a criminal for trying to improve my mental
and physical health.
Some other countries have already banned DHEA. In Australia, for example, people have been arrested, jailed, and fined thousands
of dollars for bringing a few DHEA capsules into the country. In 2005 a group of arrogant politicians in Washington tried to ban DHEA in the U.S. Their proposed legislation is currently
awaiting review by a committee. The claim, that DHEA has no medical value and is dangerous, is indeed an outright lie. Many
medical studies of DHEA supplementation have shown benefits to patients suffering from a variety of ailments that will be
discussed below.
Overview
DHEA is a substance produced by the adrenal glands, brain, skin, and other tissues. From it the body makes various hormones,
including testosterone and estradiol. DHEA is the most abundant steroid in the bloodstream; high concentrations are found
in the brain. The body’s DHEA production peaks at puberty in women and at about age 20 in men, then decreases with age.
Reviews on the subject of DHEA as a supplement
The medical literature contains many reviews of various aspects of DHEA supplementation. For a non-technical, even-handed
overview, we recommend the review by Thorne Research. A negative overview — one that reflects the dismissive attitudes of American physicians — can be read at the PDRhealth website. Other useful reviews are those by Binello, Saad, Legrain, Labrie/Luu,, and Bovenberg. A review by Webb, et al., discusses recently discovered DHEA receptors which may be responsible for some of DHEA’s most interesting
and important effects.
Research into the possible benefits of DHEA supplementation has been plagued by political controversy ever since DHEA became
popular and widely used. On the one hand, some DHEA enthusiasts and vendors have hyped the supplement far beyond the available
evidence, even going so far as to call it ‘the fountain of youth’. On the other hand, War-On-Drugs fanatics are eager to add DHEA to the ever-growing roster of illegal substances.
The medical profession and sports nutritionists have carried out a low-key campaign to discredit DHEA. Thus, many published reviews downplay the evidence of benefit or emphasize the inconsistency of research results. Reviews and reports — even when they acknowledge a significant benefit from DHEA treatment — often end with a warning that
DHEA supplements need to be studied further before they are used clinically to treat diseases. This is like telling someone who is dangling by a fraying rope over a precipice, “Ho there! We could toss you a stronger rope, but we’re going to wait until we do more tests on it.”
Despite this opposition, a great deal of good clinical research has been carried out using DHEA supplementation, and much
of it demonstrates benefits to patients suffering from a variety of diseases. The main focus has been on:
- fat and obesity
- hormone replacement
- heart disease
- cancer
- muscle building
- bone and osteoporosis
- skin
- anti-aging
- energy and fatigue
- immunity, infections
- cognition
- mood and depression
- lupus
- menopausal symptoms and fibromyalgia
- sexual function
- fertility
Other subjects that have received some attention are:
- multiple sclerosis
- Parkinson’s
- allergies and asthma
- schizophrenia
- herpes encephalitis
- diabetes
- neuronal growth and survival
Let us look briefly at what researchers have reported about these potential applications of DHEA supplementation.
Fat and obesity
In 1988 a small clinical trial was conducted in which healthy men consumed 1600 mg/day of DHEA for 28 days. The astonishing
result was an average loss of bodyfat of 31%, and a corresponding increase in muscle mass. Two other small studies at the
same dosage — one in obese young men, the other in healthy men — showed no such improvements. The discrepancies between these three studies has never been explained, but could have involved
factors such as the formulations used, or dietary, genetic, or other differences between the groups of subjects.
All later studies of the effects of DHEA on fat and muscle used far lower doses than the 1988 study and had less dramatic
results (some positive, some null). The medical profession, always ready to dismiss any new treatment that it isn’t compelled by overwhelming evidence
to accept, has therefore dismissed DHEA as a fat burner.
Nevertheless, a large dose of DHEA significantly increases the body’s metabolic rate. You can easily demonstrate this simply
by trying it yourself (1000 mg micronized DHEA taken with food) and observing the increase in body temperature and increased
warmth of your skin. An increase in metabolic rate generally causes the body to draw upon its body fat.
DHEA supplementation reduces the lipodystrophy caused by HIV drugs, and it lowers circulating cortisol levels. (The hormone cortisol promotes the storage of visceral fat — the fat that surrounds the digestive tract and can cause the belly to protrude.
Hormone replacement therapy (HRT)
In patients with impaired adrenal glands, DHEA supplementation elevates the body’s production of testosterone and estrogens.
Age-related declines in DHEA levels can be corrected with DHEA dosages of about 50 mg/day for women, 100 mg/day for men. Higher doses may be required for other purposes. Age-related declines in estrogens and testosterone can sometimes be corrected by DHEA supplementation. Low-dose studies in subjects 40-70 years of age showed that 50 mg/day
restored estrogen and testosterone to youthful levels in women, and restored estrogen levels (but not testosterone) in men.
Both sexes experienced an increase in the tissue-building hormone ‘IGF-1’ (insulin-like growth factor) and “a remarkable increase
in perceived physical and psychological well-being”. Testosterone levels in elderly men increased 46% with 6 months of DHEA supplementation at 50 mg/day.
Contrary to anti-HRT propaganda generated by neo-luddites and carried by the media, the use of hormone supplements (androgens
and estrogens) to restore youthful hormone levels is, by and large, beneficial rather than harmful for both sexes. HRT improves
the condition of skin, bone, and other tissues, improves cognition, and contributes to libido. HRT does increase the risk
of certain medical conditions, but this elevation in risk is much smaller than other risks that we take for granted, such
as those of automobile accidents or falls.
Many DHEA clinical studies have used too low a dosage of DHEA. In women, this can lead to side effects such as sleepiness,
restlessness, headache, acne, body hair growth, scalp hair loss, or odors. In men it results in a failure to raise testosterone
levels.
DHEA was used in a 2006 clinical study to treat HIV-related declines in steroid hormone levels. At 100-400 mg/day of DHEA,
significant increases in testosterone and other steroid hormone levels were achieved.
Heart disease
In 1988, Nestler, et al., reported that when healthy men were given oral doses of 1600 mg/day of DHEA, their LDL levels fell
by 7.5% in 4 weeks. Two years later the study was repeated by other researchers, who found no changes in LDL levels. (Such contradictions are not unusual in the medical research literature.) Subsequent studies have shown undramatic effects
of DHEA on cholesterol levels — but these studies used doses of 20 to 100 mg/day.
In recent years, as reviewers have tried to summarize and draw conclusions from past clinical studies, many have decided that
the 1988 results must be wrong, since they are contradicted by most later studies. They ignore the fact that the small doses used after 1990 make comparisons with Nestler’s study impossible. The discrepancy
between the 1988 and 1990 studies might easily be due to something as simple as the fineness with which the DHEA was ground
up before dosing, or whether it was consumed with food, or some other factor that was never examined by the reviewers.
So we should be skeptical about claims that DHEA supplements fail to improve cholesterol or LDL profiles, or that they are
useless for treating or preventing heart disease. Some reviewers consider this supplement to be of proven benefit to the cardiovascular
system. The last word is not yet in on these subjects.
There is less controversy over findings that cortisol levels in both sexes can be reduced by DHEA supplementation at 200 mg/day. (Cortisol correlates with heart disease.)
Indirect evidence suggests that DHEA may lower the incidence of atherosclerosis.
Cancer
DHEA treatment appears to inhibit cancers of the breast, prostate, colon, liver, and skin. Most of this evidence comes from animal experiments — very few clinical studies have addressed the issue in humans.
Most cancer-related work using DHEA has been focused on breast cancer. From epidemiological studies it is known that premenopausal
women with high blood levels of DHEA develop less breast cancer than those with low levels. There is also abundant evidence from studies in cell culture, rats, and humans, that androgens (such as testosterone and
DHEA) inhibit the proliferation of breast cancer cells. As a breast cancer therapy DHEA may be the best available androgen, since it has only mild androgenic effects in other tissues,
yet has a strong inhibitory effect in breast tissue.
Prostate cancer has also received some attention from DHEA researchers. Recent evidence suggests — in direct contradiction
to current treatment paradigms — that androgens such as testosterone protect the prostate from tumor growth. Such an anti-cancer effect has actually been demonstrated in lab animals, but no human clinical tests have been performed.
Muscle building
Does DHEA supplementation increase the size and strength of muscles? The answer will probably be “no” if you ask sports nutritionists, War-On-Drugs zealots, or the physicians’ lobby. But it will probably be “yes” if you ask medical researchers fortunuate enough
to have funding sources and social environments that allow them to study the matter objectively.
Most research into DHEA’s muscle-building capabilities has been done in elderly subjects. In a 1994 study, 50 mg/day of DHEA
for six months resulted in a 16% increase in blood levels of the hormone IGF-1 in men, and a 31% increase in women. (IGF-1 is a tissue-building hormone that promotes muscle growth.) Another study at the
same dosage showed increases in IGF-1 of 32% and muscular increases of about 2.5%.
At 100 mg/day DHEA increased muscular strength in men by 15%. Nestler’s 1988 study reported a significant increase in muscle mass in men taking 1600 mg/day.
Bone and osteoporosis
In elderly women and men, bone density increases were seen with DHEA supplementation at 50 mg/day. A 2000 study, for example, showed 1.6-2.5% increases in bone mineral density after six months of DHEA usage. Even a 25 mg/day DHEA regimen showed significant reductions in joint pain in men.
Skin
When DHEA was applied to the buttock skin of volunteers 12 times during 4 weeks it promoted the synthesis of procollagen and
protein; the researchers concluded that DHEA could be an anti-aging agent for the skin.
Improvement in skin pigmentation took place in elderly women given DHEA at 50 mg/day.
In 2005 it was reported that DHEA levels correlate strongly with protection against chronic venous ulceration in humans, and
it was shown that DHEA accelerated healing in wounded mouse skin.
Anti-aging and longevity
No clinical studies have tried to determine whether longevity is increased by DHEA use. But if DHEA ameliorates ailments of
aging (such as heart disease and cancer), then it is logical to expect an increase in longevity.
Energy and fatigue
DHEA supplementation at 200-500 mg/day significantly reduced fatigue in HIV patients. It had a similar effect in non-HIV subjects, and produced an increase in stamina in women with androgen deficiency.
Immunity
DHEA protects mice from viral, bacterial and parasitic infections by enhancing immunity. Immunity enhancement has also been been reported in humans. In a 20-week experiment, men in their 60s who were given 50 mg/day of DHEA saw major increases in measures of immunity.
Cognition
The effects of DHEA on cognition are complex, since they depend on a person’s hormonal conditions. Consequently, most studies
of the cognitive effects of DHEA in humans have produced null results — in contrast to animal studies, which have shown significant cognitive benefits.
However, patients with advanced HIV disease experienced significant improvement in cognition when they were given 50 mg/day
of DHEA for 4 months.
Mood and depression
When people with midlife-onset depression were given DHEA (3 weeks at 90 mg/day followed by 3 weeks at 450 mg/day), half of
the patients achieved a 50% reduction in depression score. In depressed schizophrenic patients, DHEA at 100 mg/day improved depression and anxiety. Dosages of DHEA in the range of 100-500 mg/day resulted in improved mood and less depression in HIV patients.
Women with low hormone levels experienced higher alertness, stamina, and initiative after using DHEA. In aging men with low androgen levels, 25 mg/day of DHEA caused a “progressive improvement in mood”.
Lupus
At 200 mg/day DHEA reduced the incidence of lupus flares, apparently because DHEA decreases the production of Interleukin-10, an inflammatory cytokine. Other research studies have shown similar results.
Menopausal symptoms
In menopausal women DHEA has been reported to reduce vasomotor symptoms, increase sexual arousal, and improve cognitive performance.
Sexual function
Clinical trials have shown that DHEA supplementation improves libido and other sexual functions in elderly women, men and women with sexual dysfunction, and younger men and women with hormone deficiencies. DHEA also decreases erectile dysfunction. Libido studies are lacking for normal young men and women.
Fertility
DHEA supplementation at 80 mg/day improved lackluster responses to ovarian stimulation. General effects on fertility have not been studied.
Other ailments
Studies in humans, monkeys, and rodents suggest other possible uses for DHEA:
- reducing incidence and severity of multiple sclerosis
- inhibiting progression or reducing symptoms of Parkinson’s
- ameliorating allergies such as atopic dermatitis and allergy-induced asthma
- preventing herpes virus type 2 encephalitis
- preventing diabetes, and increasing insulin sensitivity in diabetics
- increasing neuronal growth and survival
Because its areas of application are so broad, DHEA is used by many people for general health.
Only micronized DHEA is worth buying — non-micronized DHEA is hardly absorbed at all. A 10-20 mg dose of piperine (Bioperine®) taken with, or up to an hour before, a DHEA dose may further improve bioavailability.
— Dr. Alexis Zarkov, Ph.D.
You can contact Dr. Zarkov at AskDrZarkov@yahoo.com.
Last modified 2006.Oct.5
References
[1]
Tyranny is taking hold in Australia, too.
Supplements in the News (LifeLink) 2006.Aug
[2]
DHEA [monograph, PDF, 34KB]
Thorne.com website
[3]
DHEA [monograph]
PDRhealth website
[4]
Clinical uses and misuses of dehydroepiandrosterone.
Curr Opin Pharmacol. 2003 Dec; 3: 635-41
Binello E, Gordon CM
[5]
Dehydroepiandrosterone treatment in the aging male — what should the urologist know?
Eur. Urol. 2005 Nov; 48: 724-33; discussion 733
Saad F, Hoesl CE, Oettel M, Fauteck JD, Römmler A
[6]
Pharmacology and therapeutic effects of dehydroepiandrosterone in older subjects.
Drugs Aging. 2003;20(13):949-67
Legrain S, Girard L
[7]
Is dehydroepiandrosterone a hormone?
J. Endocrinol. 2005 Nov; 187: 169-96
Labrie F, Luu-The V, Bélanger A, Lin SX, Simard J, Pelletier G, Labrie C
[8]
Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS.
Am. J. Psychiatry. 2006 Jan; 163: 59-66
Rabkin JG, McElhiney MC, Rabkin R, McGrath PJ, Ferrando SJ
[9]
The biological actions of dehydroepiandrosterone involves multiple receptors.
Drug Metab. Rev. 2006 ; 38: 89-116
Webb SJ, Geoghegan TE, Prough RA, Michael Miller KK
[10]
[Ad for the book DHEA: Unlocking the secrets to the Fountain of Youth]
Amazon.com website
[11]
A bill to include dehydroepiandrosterone as an anabolic steroid.
Thomas "The Library of Congress" website
[12]
[DHEA and aging]
Psychol Neuropsychiatr Vieil. 2003 Jun; 1: 111-9
Pitti-Ferrandi H
[13]
The use of dehydroepiandrosterone therapy in clinical practice.
Treat Endocrinol. 2005 ; 4: 95-114
Cameron DR, Braunstein GD
[14]
Pharmacology and therapeutic effects of dehydroepiandrosterone in older subjects.
Drugs Aging. 2003 ; 20: 949-67
Legrain S, Girard L
[15]
Androgen therapy in women.
Eur. J. Endocrinol. 2006 Jan; 154: 1-11
Arlt W
[16]
Lack of effect of dehydroepiandrosterone in obese men.
Int J Obes. 1990 May; 14: 457-63
Usiskin KS, Butterworth S, Clore JN, Arad Y, Ginsberg HN, Blackard WG, Nestler JE
[17]
Failure of dehydroepiandrosterone to influence energy and protein metabolism in humans.
J. Clin. Endocrinol. Metab. 1990 Nov; 71: 1259-64
Welle S, Jozefowicz R, Statt M
[18]
Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age.
J Clin Endocrinol Metab. 1994 Jun;78(6):1360-7.
Morales AJ, Nolan JJ, Nelson JC, Yen SS
[19]
The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids,
body composition and muscle strength in age-advanced men and women.
Clin. Endocrinol. (Oxf) 1998 Oct; 49: 421-32
Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS
[20]
Peroxisomal proliferator-activated ligand therapy for HIV lipodystrophy.
Clin. Exp. Dermatol. 2001 Mar; 26: 155-61
Smith KJ, Skelton HG
[21]
Influence of DHEA administration on 24-hour cortisol concentrations.
J Clin Psychopharmacol. 2003 Feb;23(1):96-9.
Kroboth PD, Amico JA, Stone RA, Folan M, Frye RF, Kroboth FJ, Bigos KL, Fabian TJ, Linares AM, Pollock BG, Hakala C
[22]
Dehydroepiandrosterone therapy as female androgen replacement.
Semin. Reprod. Med. 2006 Apr; 24: 97-105
Saltzman E, Guay A
[23]
Dehydroepiandrosterone supplementation in women with adrenal failure: impact on twenty-four hour GH secretion and IGF-related
parameters.
Clin. Endocrinol. (Oxf) 2004 Apr; 60: 461-9
Christiansen JJ, Gravholt CH, Fisker S, Svenstrup B, Bennett P, Veldhuis J, Andersen M, Christiansen JS, Jørgensen JO
[24]
Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism.
J. Endocrinol. Invest. 2004 Sep; 27: 736-41
Libè R, Barbetta L, Dall'Asta C, Salvaggio F, Gala C, Beck-Peccoz P, Ambrosi B
[25]
Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine
parameters and synthesis of neuroactive steroids.
Fertil. Steril. 2003 Dec; 80: 1495-501
Genazzani AD, Stomati M, Bernardi F, Pieri M, Rovati L, Genazzani AR
[26]
[Adrenopause and dehydroepiandrosterone: pharmacological therapy versus replacement therapy]
Gynakol Geburtshilfliche Rundsch. 2003 Apr; 43: 79-90
Römmler A
[27]
Effects of DHEA replacement on bone mineral density and body composition in elderly women and men.
Clin. Endocrinol. (Oxf) 2000 Nov; 53: 561-8
Villareal DT, Holloszy JO, Kohrt WM
[28]
Endocrine effects of oral dehydroepiandrosterone in men with HIV infection: a prospective, randomized, double-blind, placebo-controlled
trial.
Metab. Clin. Exp. 2006 Jul; 55: 858-70
Poretsky L, Brillon DJ, Ferrando S, Chiu J, McElhiney M, Ferenczi A, Sison MC, Haller I, Rabkin J
[29]
Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in
normal men.
J. Clin. Endocrinol. Metab. 1988 Jan; 66: 57-61
Nestler JE, Barlascini CO, Clore JN, Blackard WG
[30]
Dehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies.
Eur. J. Endocrinol. 2004 Jul; 151: 1-14
Tchernof A, Labrie F
[31]
Short-term dehydroepiandrosterone treatment increases platelet cGMP production in elderly male subjects.
Clin. Endocrinol. (Oxf) 2006 Mar; 64: 260-4
Martina V, Benso A, Gigliardi VR, Masha A, Origlia C, Granata R, Ghigo E
[32]
Dehydroepiandrosterone inhibits the progression phase of mammary carcinogenesis by inducing cellular senescence via a p16-dependent
but p53-independent mechanism.
Breast Cancer Res. 2005 ; 7: R1132-40
Shilkaitis A, Green A, Punj V, Steele V, Lubet R, Christov K
[33]
Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA.
Endocr Relat Cancer. 2006 Jun;13(2):335-55
Labrie F
[34]
Dehydroepiandrosterone, androgens and the mammary gland.
Gynecol. Endocrinol. 2006 Mar; 22: 118-30
Labrie F
[35]
Prevention of prostate cancer by androgens: experimental paradox or clinical reality.
Eur. Urol. 2004 Sep; 46: 285-94; discussion 294-5
Algarté-Génin M, Cussenot O, Costa P
[36]
Testosterone prohormone supplements.
Med. Sci. Sports Exerc. 2006 Aug; 38: 1451-61
Brown GA, Vukovich M, King DS
[37]
Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue.
Proc. Natl. Acad. Sci. U.S.A. 2000 Apr; 97: 4279-84
Baulieu EE, Thomas G, Legrain S, Lahlou N, Roger M, Debuire B, Faucounau V, Girard L, Hervy MP, Latour F, Leaud MC, Mokrane
A, Pitti-Ferrandi H, Trivalle C, de Lacharrière O, Nouveau S, Rakoto-Arison B, Souberbielle JC, Raison J, Le Bouc Y, Raynaud
A, Girerd X, Forette F
[38]
Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid
therapy.
J. Rheumatol. 2005 Apr; 32: 616-21
Mease PJ, Ginzler EM, Gluck OS, Schiff M, Goldman A, Greenwald M, Cohen S, Egan R, Quarles BJ, Schwartz KE
[39]
Treatment of osteoporosis in men using dehydroepiandrosterone sulfate.
Chin. Med. J. 2002 Mar; 115: 402-4
Sun Y, Mao M, Sun L, Feng Y, Yang J, Shen P
[40]
Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial.
J. Clin. Endocrinol. Metab. 2002 Nov; 87: 4935-41
Gordon CM, Grace E, Emans SJ, Feldman HA, Goodman E, Becker KA, Rosen CJ, Gundberg CM, LeBoff MS
[41]
Long-term low-dose dehydroepiandrosterone replacement therapy in aging males with partial androgen deficiency.
Aging Male. 2004 Jun; 7: 133-43
Genazzani AR, Inglese S, Lombardi I, Pieri M, Bernardi F, Genazzani AD, Rovati L, Luisi M
[42]
Modulation of collagen metabolism by the topical application of dehydroepiandrosterone to human skin.
J. Invest. Dermatol. 2005 Feb; 124: 315-23
Shin MH, Rhie GE, Park CH, Kim KH, Cho KH, Eun HC, Chung JH
[43]
The sex steroid precursor DHEA accelerates cutaneous wound healing via the estrogen receptors.
J. Invest. Dermatol. 2005 Nov; 125: 1053-62
Mills SJ, Ashworth JJ, Gilliver SC, Hardman MJ, Ashcroft GS
[44]
DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters.
Psychoneuroendocrinology. 2000 Jan; 25: 53-68
Rabkin JG, Ferrando SJ, Wagner GJ, Rabkin R
[45]
Prospective observational study of treatments for unexplained chronic fatigue.
J. Clin. Psychiatry. 2005 May; 66: 625-32
Bentler SE, Hartz AJ, Kuhn EM
[46]
Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial.
J Clin Endocrinol Metab. 2002 May;87(5):2046-52. Related Articles, Links
Johannsson G, Burman P, Wiren L, Engstrom BE, Nilsson AG, Ottosson M, Jonsson B, Bengtsson BA, Karlsson FA
[47]
Control of the immune response by DHEA and its metabolites.
Rinsho Byori. 1998 Jun; 46: 505-17
Loria RM, Padgett DA
[48]
Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men.
J Gerontol A Biol Sci Med Sci. 1997 Jan; 52: M1-7
Khorram O, Vu L, Yen SS
[49]
Evidence that androgenic and estrogenic metabolites contribute to the effects of dehydroepiandrosterone on cognition in postmenopausal
women.
Horm. Behav. 2004 Feb; 45: 144-55
Hirshman E, Merritt P, Wang CC, Wierman M, Budescu DV, Kohrt W, Templin JL, Bhasin S
[50]
Double-blind placebo-controlled trial of oral dehydroepiandrosterone in patients with advanced HIV disease.
Clin Endocrinol (Oxf). 2001 Sep; 55: 325-30
Piketty C, Jayle D, Leplege A, Castiel P, Ecosse E, Gonzalez-Canali G, Sabatier B, Boulle N, Debuire B, Le Bouc Y, Baulieu
EE, Kazatchkine MD
[51]
Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression.
Arch. Gen. Psychiatry 2005 Feb; 62: 154-62
Schmidt PJ, Daly RC, Bloch M, Smith MJ, Danaceau MA, St Clair LS, Murphy JH, Haq N, Rubinow DR
[52]
Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia.
Arch Gen Psychiatry. 2003 Feb; 60: 133-41
Strous RD, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M, Weizman A
[53]
Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind,
placebo-controlled trial.
Arthritis Rheum. 2002 Nov;46(11):2924-7
Chang DM, Lan JL, Lin HY, Luo SF
[54]
Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus.
Ann. Rheum. Dis. 2004 Dec; 63: 1623-6
Chang DM, Chu SJ, Chen HC, Kuo SY, Lai JH
[55]
Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.
Arthritis Rheum. 2004 Sep; 50: 2858-68
Petri MA, et al.
[56]
Dehydroepiandrosterone, a sex steroid metabolite in development for systemic lupus erythematosus.
Expert Opin. Investig. Drugs. 2003 Jun; 12: 1017-25
Merrill JT
[57]
Therapeutic effects of progestins, androgens, and tibolone for menopausal symptoms.
Am J Med. 2005 Dec; 118: 88-92
Liu JH
[58]
Dehydroepiandrosterone in the treatment of erectile dysfunction in patients with different organic etiologies.
Urol Res. 2001 Aug; 29: 278-81
Reiter WJ, Schatzl G, Märk I, Zeiner A, Pycha A, Marberger M
[59]
Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series.
Hum Reprod. 2000 Oct; 15: 2129-32
Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE
[60]
Administration of dehydroepiandrosterone suppresses experimental allergic encephalomyelitis in SJL/J mice.
J Immunol. 2001 Dec; 167: 7094-101
Du C, Khalil MW, Sriram S
[61]
DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeys.
Neurobiol Aging. 2006 Nov; 27: 1684-93
Bélanger N, Grégoire L, Bédard PJ, Di Paolo T
[62]
Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia
patients: a randomized, double-blind placebo controlled trial.
Schizophr. Res. 2005 Nov; 79: 251-6
Nachshoni T, Ebert T, Abramovitch Y, Assael-Amir M, Kotler M, Maayan R, Weizman A, Strous RD
[63]
Dehydroepiandrosterone may be one of the regulators of cytokine production in atopic dermatitis.
Arch Dermatol Res. 1997 Jun; 289: 410-4
Tabata N, Tagami H, Terui T
[64]
Dehydroepiandrosterone attenuates allergic airway inflammation in Dermatophagoides farinae-sensitized mice.
J Microbiol Immunol Infect. 2002 Sep; 35: 199-202
Yu CK, Liu YH, Chen CL
[65]
Androstenediol antagonizes herpes simplex virus type 1-induced encephalitis through the augmentation of type I IFN production.
J Immunol. 1998 Mar; 160: 3060-6
Daigle J, Carr DJ
[66]
Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women.
Diabetes 2005 Mar; 54: 765-9
Dhatariya K, Bigelow ML, Nair KS
[67]
Mitotic and neurogenic effects of dehydroepiandrosterone (DHEA) on human neural stem cell cultures derived from the fetal
cortex.
Proc Natl Acad Sci U S A. 2004 Mar; 101: 3202-7
Suzuki M, Wright LS, Marwah P, Lardy HA, Svendsen CN
Disclaimer: The information provided in this “Ask Dr. Zarkov” article contains no medical advice whatsoever — it contains
‘biological information’. Nothing in the article constitutes an effort to persuade readers to use, or not to use, this biological
information as a basis for action.